Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT ID: NCT07083765

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 142 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-01
• Study Completion Date: 2027-10-31

Brief Summary

To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.

Detailed Description

This Phase 3, prospective, randomized, blinded, sham procedure-controlled, multicenter study will assess the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Catheter in hypertensive subjects in the absence of antihypertensive medications. Subjects with a documented history of uncontrolled hypertension who are taking 0, 1, or 2 antihypertensive medications at enrollment will be recruited. After providing written informed consent, subjects will undergo screening assessments to assess eligibility for the study. Eligible subjects will then enter a run in period during which they will take no antihypertensive medications. Subjects who continue to be eligible at the end of the run-in period will complete the study Baseline visit and remain without taking antihypertensive medications. Subjects who continue to be eligible after the completion of the Baseline visit will attend the study site and will be randomized to either the Treatment Arm (renal denervation using the Peregrine Catheter) or the Sham Control Arm (renal angiography only).

After study unblinding, crossover from the Sham Control Arm to the Treatment Arm may be allowed, at the discretion of the treating investigator.

Conditions

Hypertension; Hypertension,Essential

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment Arm

Renal denervation performed with dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter.

Group Type: EXPERIMENTAL

Dehydrated Alcohol Injection, USP

Intervention Type: DRUG

Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries

Sham Control Arm

Only renal angiography performed

Group Type: SHAM_COMPARATOR

Sham procedure

Intervention Type: PROCEDURE

Endovascular, renal angiography

Interventions

Dehydrated Alcohol Injection, USP

Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries

Intervention Type: DRUG

Sham procedure

Endovascular, renal angiography

Intervention Type: PROCEDURE

Other Intervention Names

Alcohol

Eligibility Criteria

Inclusion Criteria

1. Has 2 office blood pressure measurements with a mean office systolic blood pressure (SBP) of ≥150 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of ≥90 mmHg.

2. Documented history of uncontrolled hypertension and is currently taking 1 or 2 antihypertensive medications.

3. Is willing to discontinue any current antihypertensive medications for at least 13 weeks (5-week pre-procedure and 8-week post-procedure).

4. Has a mean 24-hour ambulatory SBP of ≥140 mmHg and ≤170 mmHg with required valid readings.

Exclusion Criteria

1. Has renal artery anatomy abnormalities.

2. Has previously undergone renal denervation.

3. Has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or is on chronic renal replacement therapy.

4. Has documented untreated sleep apnea.

5. Has any of the following conditions: severe cardiac valve stenosis, heart failure (New York Heart Association [NYHA] Class III or IV), chronic atrial fibrillation (defined as at least one documented episode in the 12 months before study entry), and known primary pulmonary hypertension (>60 mmHg pulmonary artery or right ventricular systolic pressure).

6. Is pregnant or lactating at the time of enrollment or planning to become pregnant during the trial time period (female subjects only).

7. Is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal pulmonary inhalants are allowed.

8. Has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within 6 months prior to the planned procedure.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ablative Solutions, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Weber, MD

Role: PRINCIPAL_INVESTIGATOR

SUNY Downstate Medical Center and College of Medicine

David Kandzari, MD

Role: PRINCIPAL_INVESTIGATOR

Piedmont Healthcare

Felix Mahfoud, Prof.Dr. med

Role: PRINCIPAL_INVESTIGATOR

University of Basel

Atul Pathak, Prof.

Role: PRINCIPAL_INVESTIGATOR

Princess Grace Hospital, Monaco

Locations

Tennova Turkey Creek Medical Center

Knoxville, Tennessee, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Missy Broich

Role: CONTACT

mbroich@ablativesolutions.com

+1 (650) 688-9743

Debbie Reynolds, PhD

Role: CONTACT

dreynolds@ablativesolutions.com

+1 (650) 688-9743

Other Identifiers

CR0041

Identifier Type: -

Identifier Source: org_study_id